Research and experimental development on natural sciences and engineering
IMMUNOQUEST THERAPEUTICS AS
Revenue 2024
NOK 0
Operating profit
NOK −718,000
Equity
NOK −721,000
Incorporated
2023
Share capital
NOK 43,000
Key figures · 2024
Current ratio
3.25
Equity ratio
-164.9%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Return on assets (%%) | -164.1% | |
| Likviditet | ||
| Current ratio | 3.25 | |
| Working capital | 281k | |
| Soliditet | ||
| Equity ratio (%%) | -164.9% | |
| Debt-to-equity ratio | -1.61 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.